AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01787695 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: UVA1
Description: Patients with a vitiligo patch larger than 25cm2 will be recruited. The target patch will be divided into two halves. One half will be shielded by foil and served as control while the other half will be exposed to UVA1.~The dose of UVA1 will be 60 J/cm2, 5 times a week for 4 weeks. Patients that have no or less than 10% pigmentation change after 4 weeks will receive UVA1 130J/cm2, 5 times a week for another 4 weeks. The patients with more than 10% pigmentation change will receive UVA1 60 J/cm2, 5times a week for another 4weeks. This will be followed by assessments at 4, 8, and 12 weeks post treatment.
Study NCT00467142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Study NCT02315963 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Performance Feedback
Description: Performance Feedback regarding the patients efforts and accomplishments during the patients stay in the rehabilitation clinic, an expected average of 6 weeks. The data available about the patients progress will be analysed and processed to create a visual illustration shown to the patient on a daily bases.
Study NCT02385708 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2% Chlorohexidine Gluconate Standard of Care
Description: Patients will perform the current standard of care treatment using 2% Chlorohexidine Gluconate Cloths on the abdomen and buttocks prior to colorectal surgery night before surgery and morning of surgery.
Study NCT02385708 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2% Chlorohexidine Gluconate Chin to Toe
Description: Patients will perform treatment with 2% Chlorohexidine Gluconate cloths chin to toe night before and morning of surgery then daily post operative until post op day 4 or discharge
Study NCT00961376 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PBMC re-infusion
Description: Autologous PBMC re-infusion
Study NCT00961376 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD25 depletion
Description: Autologous, CD25-depleted PBMC re-infusion
Study NCT02734511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sedation with propofol
Description: induction with propofol at 20mg/kg/h. Then, when the patient is sleeping, dosage is decreased to 6 mg/kg/h
Study NCT04212845 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine;Dexamethasone Solution for Injection
Description: 8 mg Dexamethasone and %0.25 bupivacaine
Study NCT04212845 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fluoroscopy
Description: Fluoroscopy-guided transforaminal injection
Study NCT04212845 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: Ultrasound-guided erector spinae plane block
Study NCT00467142 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymorphism analysis
Study NCT04037384 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Eye yoga
Description: Eye yoga exercises at home given by a trained instructor
Study NCT04037384 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Passive Reading
Description: Passive reading at home
Study NCT02802683 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine
Description: spinal anesthesia with hyperbaric bupivacaine
Study NCT02802683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: spinal anesthesia with hyperbaric bupivacaine
Study NCT02802683 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine
Description: spinal anesthesia with isobaric levobupivacaine
Study NCT02802683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine
Description: spinal anesthesia with isobaric levobupivacaine
Study NCT01413646 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Walnut Supplementation
Description: Eight weeks of walnut supplementation
Study NCT02802683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Description: continous infusion of phenylephrine
Study NCT02802683 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: continous infusion of normal saline
Study NCT02802683 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: normal saline
Description: continous infusion of normal saline
Study NCT01413646 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: No walnut supplementation
Description: Eight weeks without walnut supplementation
Study NCT00353574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darusentan
Description: Darusentan capsules administered orally once daily
Study NCT03197272 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PiXL
Description: Phototherapeutic intrastromal corneal collagen cross-linking (PiXL) performed in a high-oxygen environment without corneal epithelial debridement, for treatment of mild myopia.
Study NCT03197272 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PiXL
Description: Phototherapeutic intrastromal corneal collagen cross-linking (PiXL) performed in a high-oxygen environment without corneal epithelial debridement, for treatment of mild myopia.
Study NCT02614664 — intervention group
Intervention type: DEVICE
Intervention: NIRS
Description: Cerebral oxygenation monitor which is standard of care for this surgery.
Study NCT02537353 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Metal clips
Description: The group will be shot of adrenaline 1: 10,000 in four quadrants, associated with application of metal clips.
Study NCT02537353 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hemospray
Description: The group will be shot of adrenaline 1: 10,000 in the four quadrants associated with application adsorption powder, marketed under the name Hemospray.
Study NCT02537353 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Endoscopy Exam
Description: All patients will be submitted to endoscopy exam in 12 to 24 hours after the therapeutic procedure to confirm the success of the therapy and measure if there the presence of rebleeding.
Study NCT02537353 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopy Exam
Description: All patients will be submitted to endoscopy exam in 12 to 24 hours after the therapeutic procedure to confirm the success of the therapy and measure if there the presence of rebleeding.
Study NCT02537353 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Adrenaline
Description: The injection of adrenaline solution with 50% glucose at a proportion of 1: 10000 in four quadrants.
Study NCT00400088 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paroxetine
Description: Start at 20 mg po od. Increase dose to 40 mg po od at week 4 if there is less than 20 % reduction in MADRS scores.
Study NCT00400088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lithium
Description: start at 600mg po hs with dose to be flexibly titrated to a serum level of between 0.6 and 1.1 mmol/l.
Study NCT02184715 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: virtual reality system
Description: The participants were randomly assigned to either Group A or Group B. Group A received rehabilitation treatment and additional virtual reality system for 1 month, followed by rehabilitation treatment for 1 month; by contrast, the participants in Group B received rehabilitation treatment for 1 month, followed by rehabilitation treatment and additional virtual reality system for 1 month.
Study NCT02184715 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: virtual reality system
Description: The participants were randomly assigned to either Group A or Group B. Group A received rehabilitation treatment and additional virtual reality system for 1 month, followed by rehabilitation treatment for 1 month; by contrast, the participants in Group B received rehabilitation treatment for 1 month, followed by rehabilitation treatment and additional virtual reality system for 1 month.
Study NCT00387530 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: oral sodium phenylbutyrate
Study NCT00387530 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: valganciclovir
Study NCT02537353 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adrenaline
Description: The injection of adrenaline solution with 50% glucose at a proportion of 1: 10000 in four quadrants.
Study NCT06082622 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: laxatives
Description: triple therapy of drugs, behaviour and mental axis
Study NCT02153021 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Phototherapy
Description: phototherapy: all patientes will received application of phototherapy after exercise session. The phototherapy will be applicated in abdominal and dorsal circumference/ quadriceps and biceps femoral.~Type Ga-Al-As Wavelength 808nm Frenquency Continue wave Optical output 100mW Spot diameter 0.6mm Power density 60W/cm2 Energy per minute 6J/point Number of Points 64points Total energy delivered 48J
Study NCT02080520 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nattokinase
Study NCT02080520 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00658697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Intravenously given at 75 mg/m2 on day 1 of every 3 weeks for 4 cycles
Study NCT00658697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Intravenously given at (15 mg/kg) on day 1 of every 3 weeks for 8 cycles
Study NCT00658697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADT
Description: Either subcutaneously or intramuscularly every three months for a total of 6 doses (total of 18 months)
Study NCT00658697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Description: Starting on day 84 orally once daily until hormone therapy is completed
Study NCT00387530 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: polymerase chain reaction
Study NCT00387530 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: protein expression analysis
Study NCT02694640 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reach Plus
Description: In Months 1-3, participants in this group will receive the previously tested telephone counseling for exercise. RTR volunteers or coaches will be asked to contact participants by telephone weekly over 3 months (12 calls). In months 4-9, participants will no longer receive calls from RTR coaches and will be encouraged to use the heart rate monitors and pedometers during exercise. Participants will continue to complete their exercise logs and receive feedback reports from study staff.
Study NCT02694640 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reach Plus Phone
Description: In Months 1-3, participants in this group will receive the previously tested telephone counseling for exercise. RTR volunteers or coaches will be asked to contact participants by telephone weekly over 3 months (12 calls). In months 4-9, these participants will have the opportunity to continue to receive support calls from their coach. Participants will also continue to complete their exercise logs and receive feedback reports from study staff.
Study NCT02694640 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reach Plus Message
Description: In Months 1-3, participants in this group will receive the previously tested telephone counseling for exercise. RTR volunteers or coaches will be asked to contact participants by telephone weekly over 3 months (12 calls). In months 4-9, participants will receive messages by email or text to motivate, prompt and reinforce continued exercise. Participants will also continue to complete their exercise logs and receive feedback reports from study staff.
Study NCT00387530 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: biopsy
Study NCT04544800 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of Splint for UADT Visualization
Description: The use of a splint to assist the patient and the surgeon with UADT procedures.
Study NCT01888107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone Long-acting Injectable (LAI) 25 mg
Description: Risperidone LAI will be administered as a gluteal intramuscular injection given every 2 weeks for 52 weeks.
Study NCT01888107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone LAI 37.5 mg
Description: Risperidone LAI will be administered as a gluteal intramuscular injection given every 2 weeks for 52 weeks.
Study NCT01888107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone LAI 50 mg
Description: Risperidone LAI will be administered as a gluteal intramuscular injection given every 2 weeks for 52 weeks.
Study NCT04196062 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EndoMASTER EASE Robotic system for ESD
Description: EndoMaster EASE System, is a robotic-assisted endoscopy system indicated for endoscopic visualization and therapeutic access to the adult gastrointestinal (GI) tract for endoscopic surgery
Study NCT03780608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6738
Description: AZD6738 will be administered at 240 mg twice daily on days 1 to 7 in Cycle 0 (lead-in period) and therafter at 240 mg BD on days 22 to 28 in a 28-day cycle.
Study NCT03780608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: . Durvalumab will be administered at 1500 mg every 4 weeks from cycle 1 day 1.
Study NCT02749305 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Collection of patient-reported outcome measures
Description: Preoperative and postoperative metabolic and bariatric surgery patients will be asked to electronically complete a set of PROMs up to 21 days before surgery and annually on their surgical anniversary they will be asked to complete a postoperative PROM.
Study NCT03508596 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational intervention for the supervisors
Description: The educational intervention is based on a systematic literature review as well as focus-group interviews with health care professionals. It will be developed until the end of 2018
Study NCT03315533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine 30 milligrams (MG)
Description: Once a patient's history and screening results have been cleared by a physician investigator, the participant will be randomized by the study site investigational drug services (IDS) to receive duloxetine (30mg or 60mg) vs. placebo
Study NCT03315533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 milligrams (MG)
Description: Once a patient's history and screening results have been cleared by a physician investigator, the participant will be randomized by the study site investigational drug services (IDS) to receive duloxetine (30mg or 60mg) vs. placebo
Study NCT03315533 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Once a patient's history and screening results have been cleared by a physician investigator, the participant will be randomized by the study site investigational drug services (IDS) to receive duloxetine (30mg or 60mg) vs. placebo
Study NCT00170469 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AVA
Study NCT00170469 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rPA vaccine containing alhydrogel
Study NCT01282736 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrative Response Therapy
Description: A 10 session manualized version of IRT is employed . Each of the 10 group therapy sessions will be 60 minutes in length. Non-specialty trained Masters-level therapists will lead IRT after undergoing IRT training with the PI.
Study NCT01282736 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: A 10 session manualized version of CBT-GSH is employed . Each of the 10 group therapy sessions will be 60 minutes in length. Non-specialty trained Masters-level therapists will lead CBT-GSH after undergoing CBT-GSH training with the PI.
Study NCT02182596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mylotarg
Description: Dose level study
Study NCT03272685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Very Low Nicotine Content Cigarettes
Description: 0.4 mg nicotine/g tobacco; 9 mg tar
Study NCT03272685 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Nicotine Content Cigarettes
Description: 15.8 mg nicotine/g tobacco; 9 mg tar
Study NCT03850938 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional Kyphoplasty
Description: The cement is injected into the cavity created by PKP. The diffusion of cement can be interfered by closely barriers formed by surrounding cancellous bones.
Study NCT03850938 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Kyphoplasty with Rotary Cutter
Description: The rotary cutter is applied before cement injection to destroy the structure around the cavity created by inflated balloon. Then, the rotary cutter will make the bone cement to support a wider range and to blend with the surrounding cancellous bones more densely.
Study NCT01129986 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DermaStream
Description: Five treatment days. On each day DermaStream application for up to 4 hours of saline streaming.
Study NCT00948207 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: My Living Story
Description: Components include:~1. Life Review Interview by phone (questions based on Chochinov, 2002 dignity enhancing interview);~2) Edited transcript is delivered in a word format on...;~3) miLivingStory, a personal social network, where participants can manage content, design and layer; invite and manage their fiends and family.~4) miStory, a life review education website and portal to websites for: cancer information, databases to do your own research, social support, interactive planning tools, and a page to add their own weblinks.
Study NCT00948207 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: My Living Story
Description: Components include:~1. Life Review Interview by phone (questions based on Chochinov, 2002 dignity enhancing interview);~2) Edited transcript is delivered in a word format on...;~3) miLivingStory, a personal social network, where participants can manage content, design and layer; invite and manage their fiends and family.~4) miStory, a life review education website and portal to websites for: cancer information, databases to do your own research, social support, interactive planning tools, and a page to add their own weblinks.
Study NCT00948207 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: My Own Resources
Description: miOwnResources is a personalized, password-protected web portal to high quality websites that provide cancer information, cancer research databases for do your own research, social support, and interactive planning tools. miOwnResources also has a page for participants to add their own weblinks.
Study NCT04350476 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: VitalConnect Vital Sign Patch
Description: This patch provides continuous real-time monitoring of cardiac telemetry, heart rate, respiratory rate and oxygen saturation. Duration of monitoring is typically up to 7 days.~This patch is applied to the upper left side of the chest wall, attached with a hypoallergenic adhesive material. (This device is FDA approved for this indication).
Study NCT03900312 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Asdzaan Be'eena' Program
Description: The program will consist of 11 sessions conducted with girls ages 8-11 and their female caregivers. 5 of the 11 sessions will be taught to groups of 8-12 girls and their mothers, and 6 of the sessions will be taught to individual girl/female caregivers' dyads. The mix of group- and home-based lessons is based on findings from the formative phase about preference for certain topics to be taught in groups vs. individual dyads. Each of the sessions (group and individual) will be 60-90 minutes in duration and delivered by a trained Family Health Coach (FHC). Group sessions will take place at a local community center in a private room. Individual dyad sessions will take place in the girls'/female caregivers home or another private place of their choosing such as our local Johns Hopkins offices. The program will be conducted over 2.5-3 months with one session occurring every week for 11 weeks.
Study NCT04182607 — intervention group
Intervention type: PROCEDURE
Intervention: kidney transplant
Description: Clinical data will be collected from electronic medical records (EMRs) on donors and recipients who underwent a minimally invasive kidney transplantation procedure
Study NCT05511740 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Afternoon Radiation
Description: Melatonin, a hormone of the pineal gland, which levels are characteristic of circadian patterns, regulated with low levels of excretion in the afternoon, rises gradually during the night, peaks at dawn, and falls back in the afternoon and late afternoon. Many studies prove the function and potential of melatonin as circadian biomarkers and well correlated with the development of cancer.The function of melatonin is as an antiproliferation substance or hormone, induces apoptosis, inhibits invasion and metastasis.